GUJTHEM

Gujarat Themis Biosyn Share Price

₹275.25 +2.6 (0.95%)

03 May, 2025 05:58

SIP TrendupStart SIP in GUJTHEM

Start SIP

Performance

  • Low
  • ₹268
  • High
  • ₹280
  • 52 Week Low
  • ₹208
  • 52 Week High
  • ₹330
  • Open Price₹272
  • Previous Close₹276
  • Volume91,405

Investment Returns

  • Over 1 Month + 1.25%
  • Over 3 Month -4.56%
  • Over 6 Month -8.71%
  • Over 1 Year + 0.57%
SIP Lightning

Smart Investing Starts Here Start SIP with Gujarat Themis Biosyn for Steady Growth!

Invest Now

Gujarat Themis Biosyn Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 57
  • PEG Ratio
  • -13.6
  • Market Cap Cr
  • 2,999
  • P/B Ratio
  • 13.4
  • Average True Range
  • 18.94
  • EPS
  • 4.83
  • Dividend Yield
  • 0.1
  • MACD Signal
  • 6.29
  • RSI
  • 48.29
  • MFI
  • 76.87

Gujarat Themis Biosyn Financials

Gujarat Themis Biosyn Technicals

EMA & SMA

Current Price
₹275.25
+ 2.6 (0.95%)
  • stock-down_img
  • Bearish Moving Average 0
  • stock-up_img
  • Bullish Moving Average 0
  • 20 Day
  • ₹281.42
  • 50 Day
  • ₹277.92
  • 100 Day
  • ₹285.05
  • 200 Day
  • ₹286.69

Resistance and Support

272.37 Pivot Speed
  • R3 292.03
  • R2 284.52
  • R1 279.88
  • S1 267.73
  • S2 260.22
  • S3 255.58

What's your outlook on Gujarat Themis Biosyn?

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Gujarat Themis Biosyn has an operating revenue of Rs. 155.07 Cr. on a trailing 12-month basis. An annual revenue growth of 12% is good, Pre-tax margin of 47% is great, ROE of 29% is exceptional. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading below to its key moving averages. It needs to take out these levels and stay above it to make any meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 38 which is a POOR score indicating inconsistency in earnings, a RS Rating of 57 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at A- which is evident from recent demand for the stock, Group Rank of 52 indicates it belongs to a fair industry group of Medical-Generic Drugs and a Master Score of C is fair but needs to improve. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Gujarat Themis Biosyn Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-02-14 Quarterly Results
2024-10-25 Quarterly Results
2024-07-26 Quarterly Results
2024-05-14 Audited Results, Dividend & Bonus issue
2024-02-10 Quarterly Results & Interim Dividend
Date Purpose Remarks
2024-02-22 INTERIM Rs.0.75 per share(75%)Interim Dividend
2022-12-02 INTERIM Rs.4.40 per share(88%)Interim Dividend
2021-11-25 INTERIM Rs.2.00 per share(40%)Interim Dividend
2021-11-25 SPECIAL Rs.5.00 per share(100%)Special Dividend
View More
Date Purpose Remarks
2023-10-10 Split Rs.0.00 split from Rs. 5/- to Re. 1/-.
Date Purpose Remarks
2024-08-09 Bonus Re.0.00 issue in the ratio of 1:2 of Re. 1/-.

Gujarat Themis Biosyn F&O

Gujarat Themis Biosyn Shareholding Pattern

70.86%
1.16%
1.47%
0%
19.75%
6.76%

About Gujarat Themis Biosyn

  • NSE Symbol
  • GUJTHEM
  • BSE Symbol
  • 506879
  • ISIN
  • INE942C01045

Similar Stocks to Gujarat Themis Biosyn

Gujarat Themis Biosyn FAQs

Gujarat Themis Biosyn share price is ₹275 As on 03 May, 2025 | 05:44

The Market Cap of Gujarat Themis Biosyn is ₹2999.3 Cr As on 03 May, 2025 | 05:44

The P/E ratio of Gujarat Themis Biosyn is 57 As on 03 May, 2025 | 05:44

The PB ratio of Gujarat Themis Biosyn is 13.4 As on 03 May, 2025 | 05:44

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23